Marker Therapeutics
Minneapolis
About Marker Therapeutics
Marker Therapeutics is a clinical stage immuno-oncology company focused on developing adoptive non-gene modified T cell therapies for the treatment of hematologic malignancies such as Acute Myeloid Leukemia, Lymphoma, and Multiple Myeloma. Marker’s MultiTAA technology selectively expands non-engineered T cells, enhancing them with the ability to kill tumor cells by targeting multiple tumor-associated antigens simultaneously to prevent immune escape and generate durable immunity. Patient/donor T cells are not genetically modified and therefore the cost of generating Marker’s therapies is significantly reduced.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $136.2M
- Funding stage: IPO
- Last round: Grant (Jan 2026)
- Ticker: nasdaq:MRKR
- Website: markertherapeutics.com
- Phone: (713) 400-6400
Industries & Categories
Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/marker-therapeutics-37495 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.